UNSPSC 51143700: Combination CNS medications

This classification denotes combination drugs and preparations that affect the main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges, or the Central Nervous System or CNS, hence the term CNS MEDICATIONS. Typical combination CNS medication constituents are acetaminophen, amitriptyline, benactyzine, calcium gluconate, camphor, dextromethorphan, diphenhydramine, fluoxetine, liver, and niacin.

UNSPSC 51143700 Combination CNS medications is a Class code under which state and local governments procure naloxone products, generic multi-source pharmaceuticals, and over-the-counter health commodities for community health initiatives, pharmacy benefit programs, and institutional distribution networks. Recent solicitations show purchasing bodies acquiring both emergency-response medications (naloxone kits for overdose intervention) and broader pharmaceutical inventories through cooperative purchasing mechanisms and direct-to-manufacturer arrangements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Texas Health and Human Services Commission appear as recent active buyers.

Geographically, recent activity centers on Florida, Texas, and Minnesota through the multistate cooperative mechanism. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to its Community Health Building in Sanford. The Texas HHS Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers with pricing evaluated at 75 percent weight and contract effectiveness set for July 1, 2026. Vendors pursuing these contracts must demonstrate cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized pharmaceutical wholesalers, carry substantial professional liability and commercial general liability insurance, and meet E-Verify and drug-free workplace requirements.